Condition category
Not Applicable
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
Capsinoids (CSN), the novel non-pungent capsaicin analogs reported to promote metabolic health and exercise tolerance. Previous literature revealed that capsinoids administration could enhance fat oxidation, as well as suppress the body fat accumulation in humans. However, the vital molecular mechanism remains under investigation, as CSN considering as an ergogenic aid to enhance fat oxidation and energy restore. This study investigated the effect of post-exercise CSN supplementation on energy reliance, muscle glycogen resynthesis and changes in GLUT4 and p-Akt/Akt protein expressions in the skeletal muscle of young adults, during recovery.

Who can participate?
Nine healthy adult male volunteers (aged 21.4±0.2 years, height 171.8±1.8 cm, weight 64.9±4.3 kg, BMI 21.9±1.3 kg / m2, VO2max 47.1±1.8 ml/kg/min) of the Department of Physical Education, National Taichung University of Education participated in this study.

What does the study involve?
All subjects performed a crossover study and randomized to capsinoids and placebo trials. Participants undergo a cycling exercise challenge, muscle biopsied, blood and gaseous samples collect for analysis of metabolism, with a maximum interval from the beginning to the end of tests of two days.

What are the possible benefits and risks of participating?
The benefits for participants are to understand their own data related exercise physiology measurements and improve individual currently existing knowledge in the field of sports physiology. However, there were no possible risks existing in this experimental process because previous results have been published in SCI Journals using similar study design and experimental process.

Where is the study run from?
National Taichung University of Education.

When is the study starting and how long is it expected to run for?
August 2016 to January 2017

Who is funding the study?
Ministry of Science and Technology in Taiwan.

Who is the main contact?
Professor I-Shiung Cheng

Trial website

Contact information



Primary contact

Prof I-Shiung Cheng


Contact details

Department of Physical Education
National Taichung University of Education
No 140 Minsheng Road
West Dist

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number

CCH IRB No. : 131233

Study information

Scientific title

Fffect of acute post-exercise capsinoids supplementation on energy substrate utilization in young adults



Study hypothesis

We hypothesized that oral CSN supplementation immediately after exercise may increase the fat oxidation and whole-body insulin sensitivity resulting as to replenish the muscle glycogen levels during post-exercise recovery. Therefore, we measured the glycogen concentration, GLUT4 expression, glucose/insulin, and gaseous exchange data to explore the evidence that post-exercise CSN supplementation could alter energy reliance and enhance glycogen content in skeletal muscle of young men.

Ethics approval

Approved 04/03/2016, the Ethics Committee and Institutional Review Board (IRB) of Changhua Christian Hospital (50006 No. 20 Jianbao Street, Changhua City, Taiwan;; +886-4-7238595), ref: CCH IRB No.131233.

Study design

Randomised cross-over trial

Primary study design


Secondary study design

Randomised cross over trial

Trial setting


Trial type


Patient information sheet

See additional files (Chinese)


All participants in this study were non-alcoholics and non-smokers with a stable medical condition. To avoid the influence of other factors on results, participants were instructed to have a balanced diet and healthy lifestyle. In addition, the consumption of caffeine, tea, and tobacco was strictly prohibited during the experimental period.


Participants in this crossover designed study were randomly assigned into two trials, including placebo and CSN (capsinoids).

All participants performed a 60-min cycling exercise on an ergometer at 70% VO2max. While performing the exercise and during recovery, participants had free access to drinking water. Then, immediately after a 60-min exercise, subjects ingested with CSN or placebo capsules (12 mg) and a high-carbohydrate meal within 10-min. Each meal consisted of 80% carbohydrate (2 g/kg body weight), 8% fat, 12% protein, and overall GI was 76·6 with an average weight of 184±7 g. The items in carbohydrate meal include corn flakes (Kellogg’s Ltd, Manchester, UK), skimmed milk, white bread, strawberry jam, glucose water, and water.

Muscle biopsies were performed immediately (0h) and 3h after exercise, and collected vastus lateralis muscle samples were stored at -80°C for further analyses. Simultaneously, blood and gaseous samples were collected before, immediately after exercise (0h) and during the 3h post-exercise recovery period.

We choose the dose of 12 mg of CSN as an oral supplement, which is also a similar dosage to the human study of Josse and colleagues. The CSN capsules were purchased from the Ajinomoto Co Inc (Ajinomoto, Tokyo, Japan).

The same trial was repeated following the 2-week washout interval with the same dose of CSN and placebo capsules.

Intervention type



Drug names

Primary outcome measure

1. Glycogen levels in biopsied skeletal muscles are measured using an aseptic technique, an incision (10 mm length and depth) was made in the skin and muscle fascia at about 20 cm above the knee of the right leg at 0-h (immediately after exercise) and 3-h after exercise.
2. Fat oxidation rate in a gaseous sample is measured using MetaMax3B indirect calorimetry (Cortex Biophysik, Nonnenstrasse, Leipzing, Germany) to collect individual’s gaseous samples at every 60-min during 3h post-exercise recovery i.e., at 60, 120 and 180-min after exercise for both trials.

Secondary outcome measures

1. p-Akt/Akt ratio is measured using Western blot in muscle biopsied samples at 0-h and 3-h after exercise.
2. GLUT4 expression using Western blot in muscle samples at 0-h and 3-h after exercise.
3. Blood glucose is measured using an automated glucose analyzer supplied by YSI Life Sciences (Yellow Springs, OH, USA) at every 30-min during 3h post-exercise recovery.
4. Insulin is measured using commercially available kits (Randox, Antrim, UK) on an automated analyzer (Hitachi 7020, Tokyo, Japan). at every 30-min during 3h post-exercise recovery.
5. NEFA is measured using commercially available kits (Randox, Antrim, UK) on an automated analyzer (Hitachi 7020, Tokyo, Japan). at every 30-min during 3h post-exercise recovery.
6. Glycerol concentrations are measured using commercially available kits (Randox, Antrim, UK) on an automated analyzer (Hitachi 7020, Tokyo, Japan). at every 30-min during 3h post-exercise recovery.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Healthy male college student.
2. Non-alcoholic.
3. Non-smoker.
4. Stable medical condition.

Participant type

Healthy volunteer

Age group




Target number of participants


Participant exclusion criteria

1. Can’t follow the suggestions of a balanced diet 3 days before the experimental process.
2. Consume caffeine, tea, and tobacco and can’t be strictly prohibited during the experimental period.
3. Can’t tolerance the cycling exercise challenge including VO2max test and completed a 60-min cycling exercise at 70% VO2max.

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

National Taichung University of Education
No 140 Minsheng Road, West Dist, Taichung City, Taiwan

Sponsor information


Ministry of Science and Technology

Sponsor details

No. 106
Section 2
Heping East Road

Sponsor type





Funder type


Funder name

Ministry of Science and Technology, Taiwan

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Planned publication in the PLOS ONE Journal.

IPD sharing statement: the data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

16/08/2019: The participant information sheet was uploaded. 05/08/2019: Trial's existence confirmed by the Ethics Committee and Institutional Review Board of Changhua Christian Hospital.